Circulating tumor cells: clinical validity and utility.

Abstract

Circulating tumor cells (CTCs) are rare tumor cells and have been investigated as diagnostic, prognostic and predictive biomarkers in many types of cancer. Although CTCs are not currently used in clinical practice, CTC studies have accumulated a high level of clinical validity, especially in breast, lung, prostate and colorectal cancers. In this review, we present an overview of the current clinical validity of CTCs in metastatic and non-metastatic disease, and the main concepts and studies investigating the clinical utility of CTCs. In particular, this review will focus on breast, lung, colorectal and prostate cancer. Three major topics concerning the clinical utility of CTC are discussed-(1) treatment based on CTCs used as liquid biopsy, (2) treatment based on CTC count or CTC variations, and (3) treatment based on CTC biomarker expression. A summary of published or ongoing phase II and III trials is also presented.

• Authors: Luc Cabel, Charlotte Proudhon, Hugo Gortais, Delphine Loirat, Florence Coussy, Jean-Yves Pierga, François-Clément Bidard
• Journal: International journal of clinical oncology (Int J Clin Oncol) Vol. 22 Issue 3 Pg. 421-430 (Jun 2017) ISSN: 1437-7772 [Electronic] Japan
• PMID: 28238187 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers, Tumor

Topics

• Biomarkers, Tumor (metabolism)
• Biopsy
• Breast Neoplasms (pathology)
• Colorectal Neoplasms (pathology)
• Female
• Humans
• Lung Neoplasms (pathology)
• Male
• Neoplasms (mortality, pathology, therapy)
• Neoplastic Cells, Circulating (metabolism, pathology)
• Pathology, Clinical (methods)
• Prognosis
• Prostatic Neoplasms (pathology)